Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.
Yuan-Jie DingChung-Kuang LuWei-Ming ChenShui-Yi TungKuo-Liang WeiChen-Heng ShenYung-Yu HsiehChih-Wei YenKao-Chi ChangWen-Nan ChiuChao-Hung HungSheng-Nan LuTe-Sheng ChangPublished in: Journal of gastroenterology and hepatology (2021)
Pangenotypic DAAs are well tolerated by and yield high SVR rates in patients with mixed genotype HCV infection.